[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2013005849A - Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2. - Google Patents

Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.

Info

Publication number
MX2013005849A
MX2013005849A MX2013005849A MX2013005849A MX2013005849A MX 2013005849 A MX2013005849 A MX 2013005849A MX 2013005849 A MX2013005849 A MX 2013005849A MX 2013005849 A MX2013005849 A MX 2013005849A MX 2013005849 A MX2013005849 A MX 2013005849A
Authority
MX
Mexico
Prior art keywords
bcl
treatment
methods
activity
inhibitors
Prior art date
Application number
MX2013005849A
Other languages
English (en)
Other versions
MX346201B (es
Inventor
Steven Elmore
Tariq Ghayur
Andrew Souers
Li Chun Wang
Stuart J Perper
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45218888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013005849(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2013005849A publication Critical patent/MX2013005849A/es
Publication of MX346201B publication Critical patent/MX346201B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere a métodos para tratar lupus sistémico eritematoso, nefritis lúpica o síndrome de Sjögren con compuestos que selectivamente inhiben la actividad de proteínas Bcl-2 anti-apoptóticas. Específicamente, la presente invención está dirigida al tratamiento con compuestos que selectivamente inhiben la actividad de proteínas Bcl-2, con una afinidad menor para inhibir la actividad de otras proteínas de la familia Bcl-2, incluyendo Bcl-xL.
MX2013005849A 2010-11-23 2011-11-22 Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2. MX346201B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41668910P 2010-11-23 2010-11-23
PCT/US2011/061769 WO2012071374A1 (en) 2010-11-23 2011-11-22 Methods of treatment using selective bcl-2 inhibitors

Publications (2)

Publication Number Publication Date
MX2013005849A true MX2013005849A (es) 2013-07-05
MX346201B MX346201B (es) 2017-03-09

Family

ID=45218888

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013005849A MX346201B (es) 2010-11-23 2011-11-22 Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.
MX2017000835A MX377232B (es) 2010-11-23 2011-11-22 Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017000835A MX377232B (es) 2010-11-23 2011-11-22 Metodos de tratamiento para utilizar inhibidores selectivos de bcl-2.

Country Status (36)

Country Link
US (5) US20120129853A1 (es)
EP (2) EP3028702B1 (es)
JP (2) JP5876067B2 (es)
KR (3) KR20190109590A (es)
CN (2) CN105664164B (es)
AR (1) AR083946A1 (es)
AU (2) AU2011332000B2 (es)
BR (1) BR112013012854B1 (es)
CA (1) CA2820618C (es)
CL (1) CL2013001458A1 (es)
CR (1) CR20130268A (es)
CY (1) CY1118442T1 (es)
DK (1) DK2642999T3 (es)
DO (1) DOP2017000056A (es)
EC (1) ECSP13012710A (es)
ES (2) ES2701603T3 (es)
GT (1) GT201300136A (es)
HR (1) HRP20161762T1 (es)
HU (1) HUE031267T2 (es)
IL (2) IL226490A (es)
LT (1) LT2642999T (es)
MX (2) MX346201B (es)
MY (2) MY191300A (es)
NZ (2) NZ708508A (es)
PH (2) PH12013501006A1 (es)
PL (1) PL2642999T3 (es)
PT (1) PT2642999T (es)
RS (1) RS55545B1 (es)
RU (1) RU2593231C2 (es)
SG (2) SG190399A1 (es)
SI (1) SI2642999T1 (es)
TW (2) TWI535701B (es)
UA (2) UA119150C2 (es)
UY (1) UY33746A (es)
WO (1) WO2012071374A1 (es)
ZA (1) ZA201303589B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
MY191929A (en) 2010-06-03 2022-07-18 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US20120277210A1 (en) 2010-10-29 2012-11-01 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
KR20190109590A (ko) 2010-11-23 2019-09-25 애브비 아일랜드 언리미티드 컴퍼니 선택적인 ｂｃｌ­２ 억제제를 사용하는 치료 방법
HRP20171754T1 (hr) 2010-11-23 2017-12-29 Abbvie Inc. Soli i kristalni oblici agensa za induciranje apopotoze
WO2013090645A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP2892557A1 (en) 2012-09-07 2015-07-15 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
US20150241429A1 (en) * 2012-09-11 2015-08-27 Hospital For Special Surgery Irhom2 inhibition for the treatment of complement mediated disorders
ES2683378T3 (es) 2013-03-13 2018-09-26 Abbvie Inc. Procedimientos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
MX2016009753A (es) 2014-01-28 2017-07-07 Buck Inst For Res On Aging Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US11331328B2 (en) * 2014-05-05 2022-05-17 Bioventures, Llc Compositions and methods for inhibiting antiapoptotic Bcl-2 proteins as anti-aging agents
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
KR20180035905A (ko) 2015-08-10 2018-04-06 다나-파버 캔서 인스티튜트 인크. Bet 브로모도메인 억제제에 대한 저항성의 메카니즘
KR102124715B1 (ko) 2015-11-03 2020-06-18 제넨테크, 인크. 암의 치료를 위한 bcl-2 억제제 및 mek 억제제의 조합물
EP3445452A4 (en) 2016-04-21 2019-10-30 BioVentures, LLC COMPOUNDS FOR INDUCING THE DEGRADATION OF ANTIAPOPTOTIC PROTEINS OF THE BCL-2 FAMILY AND USES THEREOF
ES2849959T3 (es) 2016-08-05 2021-08-24 Univ Michigan Regents Derivados de N-(fenilsulfonil)benzamida como inhibidores de Bcl-2
ES3028360T3 (en) 2017-06-26 2025-06-19 Shenzhen Targetrx Inc Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof
US11480568B2 (en) 2017-09-28 2022-10-25 Yeda Research And Development Co. Ltd. Diagnosis of autoimmune diseases
BR112020014169A2 (pt) 2018-01-10 2020-12-08 Recurium Ip Holdings, Llc Compostos de benzamida
JP7385284B2 (ja) 2018-01-22 2023-11-22 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー 癌処置のためのｂｃｌ－２タンパク質分解剤
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
AU2019314624B2 (en) 2018-07-31 2022-03-03 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
CN110776507B (zh) 2018-07-31 2020-12-18 苏州亚盛药业有限公司 Bcl-2抑制剂与化疗药的组合产品及其在预防和/或治疗疾病中的用途
MX2020009759A (es) 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
TWI824010B (zh) 2018-09-18 2023-12-01 加拿大商聖諾康生命科學公司 治療血癌之組合療法
CN116199686A (zh) 2018-10-29 2023-06-02 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物
CN113825754B (zh) 2019-05-24 2023-09-22 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
WO2021078301A1 (zh) * 2019-10-24 2021-04-29 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
CN113444078B (zh) * 2020-03-25 2023-07-07 中国科学院上海有机化学研究所 抗凋亡蛋白Bcl-2抑制剂及其制备方法和应用
AU2021259861A1 (en) 2020-04-24 2022-11-17 Genentech, Inc. Methods of using anti-CD79b immunoconjugates
EP4129998A4 (en) 2020-04-29 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CRYSTAL OF A TRIFLUOROMETHYL/CHLORODISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR
EP4199924A4 (en) * 2020-08-21 2024-08-28 Ascentage Pharma (Suzhou) Co., Ltd. COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
US11834450B2 (en) * 2021-03-19 2023-12-05 Eil Therapeutics, Inc. Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CN117377672A (zh) 2021-06-04 2024-01-09 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类化合物的磷酸酯
IT202100025976A1 (it) 2021-10-06 2023-04-06 Univ Degli Studi Di Perugia Combinazione di principi attivi per il trattamento della leucemia acuta mieloide (LAM) con mutazione della nucleofosmina (NPM1)
WO2024102890A2 (en) * 2022-11-11 2024-05-16 The Board Of Regents Of The University Of Texas System Amino acid-benzoic acid oligomers and methods of use thereof for treating cancer

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2128208A (en) 1937-02-27 1938-08-23 Du Pont Alkoxy derivatives of methacrylic acid esters and method of producing them
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
WO1997010223A1 (en) 1995-09-15 1997-03-20 Pharmacia & Upjohn Company Aminoaryl oxazolidinone n-oxides
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
EP1094816B1 (en) 1998-07-06 2008-12-10 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
EP1100496A4 (en) * 1998-07-21 2002-10-23 Univ Jefferson SMALL PROTEIN INHIBITOR MOLECULES BCL-2
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CN1217936C (zh) 1999-12-28 2005-09-07 卫材株式会社 含有磺酰胺的杂环化合物
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
BR0210078A (pt) 2001-06-06 2004-06-22 Lilly Co Eli Composto, uso do mesmo, e, formulação farmacêutica
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US20090247613A1 (en) 2002-02-20 2009-10-01 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF B-CELL CLL/LYMPHOMA-2 (BCL2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7612077B2 (en) 2002-02-26 2009-11-03 Astrazeneca Ab Crystalline forms of the anti-cancer compound ZD1839
DK1480679T3 (da) 2002-02-26 2007-09-03 Astrazeneca Ab Farmaceutisk formulering af iressa, der omfatter et vandoplöseligt cellulosederivat
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JO2479B1 (en) 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
WO2005024636A1 (ja) 2003-09-04 2005-03-17 Hitachi Ulsi Systems Co., Ltd. 半導体装置
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
ATE429423T1 (de) 2004-07-20 2009-05-15 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
JP5128948B2 (ja) 2004-08-27 2013-01-23 ニッポネックス インコーポレイテッド 癌の治療のための新規な薬剤組成物
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
JP5132550B2 (ja) 2005-05-12 2013-01-30 アボット・ラボラトリーズ アポトーシス促進剤
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
AU2006247322A1 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
DK1893612T3 (da) 2005-06-22 2011-11-21 Plexxikon Inc Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20070202077A1 (en) 2005-12-02 2007-08-30 Brodsky Robert A Use of High-Dose Oxazaphosphorine Drugs for Treating Immune Disorders
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US7842681B2 (en) 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
US20080182845A1 (en) 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
ES2524340T3 (es) 2007-04-19 2014-12-05 Concert Pharmaceuticals Inc. Compuestos de morfinilino deuterados
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
WO2009039553A1 (en) * 2007-09-27 2009-04-02 The Walter And Eliza Hall Institute Of Medical Research Benzothiazole compounds
WO2009045464A1 (en) * 2007-10-01 2009-04-09 The Johns Hopkins University Methods of treating neurological autoimmune disorders with cyclophosphamide
EP2197957A1 (en) 2007-10-01 2010-06-23 Arkema, Inc. Blends of biodegradable polymers and acrylic copolymers
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US9115061B2 (en) * 2007-10-19 2015-08-25 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
US20090131363A1 (en) 2007-10-26 2009-05-21 Harbeson Scott L Deuterated darunavir
NZ585085A (en) 2007-11-16 2012-08-31 Abbott Lab Method of treating arthritis using arylsulfonamide compounds
US20090149461A1 (en) 2007-12-06 2009-06-11 Abbott Laboratories Method of treating cancer
CN101481363B (zh) * 2008-01-10 2011-05-04 江苏豪森药业股份有限公司 一种制备瑞格列奈的方法
NZ600979A (en) 2008-01-15 2014-01-31 Abbott Lab Improved mammalian expression vectors and uses thereof
CA2721615A1 (en) * 2008-04-15 2009-10-22 Burnham Institute For Medical Research An inhibitor of anti-apoptotic proteins
NZ592719A (en) 2008-10-07 2012-09-28 Astrazeneca Uk Ltd PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RS55176B1 (sr) * 2008-12-05 2017-01-31 Abbvie Inc Derivati sulfonamida kao bcl-2 selektivna sredstva koja indukuju apoptozu za lečenje karcinoma i imunskih bolesti
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) * 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
US20120094963A1 (en) 2008-12-23 2012-04-19 of Queen Elizabeth near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
CA2747837A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2010204554B2 (en) 2009-01-19 2013-05-30 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
PH12015500297B1 (en) * 2009-05-26 2023-10-20 Abbvie Ireland Unlimited Co Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US20120277210A1 (en) 2010-10-29 2012-11-01 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
KR20190109590A (ko) * 2010-11-23 2019-09-25 애브비 아일랜드 언리미티드 컴퍼니 선택적인 ｂｃｌ­２ 억제제를 사용하는 치료 방법
HRP20171754T1 (hr) 2010-11-23 2017-12-29 Abbvie Inc. Soli i kristalni oblici agensa za induciranje apopotoze

Also Published As

Publication number Publication date
AU2011332000A1 (en) 2013-06-06
HRP20161762T1 (hr) 2017-02-24
TWI535701B (zh) 2016-06-01
DK2642999T3 (en) 2017-01-09
MX377232B (es) 2025-03-04
IL251845A0 (en) 2017-06-29
PL2642999T3 (pl) 2017-04-28
US20160235760A1 (en) 2016-08-18
SI2642999T1 (sl) 2017-01-31
UY33746A (es) 2012-06-29
NZ610746A (en) 2015-06-26
PT2642999T (pt) 2017-01-05
RU2013128544A (ru) 2014-12-27
CY1118442T1 (el) 2017-06-28
MY165884A (en) 2018-05-18
ECSP13012710A (es) 2013-08-30
CA2820618C (en) 2020-04-21
PH12013501006A1 (en) 2022-03-30
ES2701603T3 (es) 2019-02-25
IL251845B (en) 2019-06-30
UA113157C2 (xx) 2016-12-26
HUE031267T2 (en) 2017-06-28
IL226490A0 (en) 2013-07-31
UA119150C2 (uk) 2019-05-10
PH12016500939A1 (en) 2017-06-14
BR112013012854A2 (pt) 2016-08-23
JP6215368B2 (ja) 2017-10-18
KR20190109590A (ko) 2019-09-25
CL2013001458A1 (es) 2013-10-04
PH12016500939B1 (en) 2018-11-09
TWI620736B (zh) 2018-04-11
KR20140004659A (ko) 2014-01-13
DOP2017000056A (es) 2017-03-31
WO2012071374A1 (en) 2012-05-31
LT2642999T (lt) 2017-01-25
BR112013012854B1 (pt) 2019-08-06
NZ708508A (en) 2016-06-24
KR20180030257A (ko) 2018-03-21
GT201300136A (es) 2014-08-05
JP2013543896A (ja) 2013-12-09
AR083946A1 (es) 2013-04-10
US9345702B2 (en) 2016-05-24
KR101841084B1 (ko) 2018-03-23
US20170232000A9 (en) 2017-08-17
US9872861B2 (en) 2018-01-23
BR112013012854A8 (pt) 2018-01-16
AU2011332000B2 (en) 2016-07-07
SG190399A1 (en) 2013-06-28
CN105664164A (zh) 2016-06-15
TW201302705A (zh) 2013-01-16
MY191300A (en) 2022-06-14
CN103402521A (zh) 2013-11-20
US20200222413A1 (en) 2020-07-16
US20180369250A1 (en) 2018-12-27
ES2603129T3 (es) 2017-02-23
EP3028702B1 (en) 2018-09-12
EP3028702A1 (en) 2016-06-08
RU2593231C2 (ru) 2016-08-10
CA2820618A1 (en) 2012-05-31
ZA201303589B (en) 2014-07-30
AU2016204396A1 (en) 2016-07-14
US20150150870A1 (en) 2015-06-04
JP5876067B2 (ja) 2016-03-02
CR20130268A (es) 2013-10-17
JP2016117744A (ja) 2016-06-30
AU2016204396B2 (en) 2017-10-26
EP2642999B1 (en) 2016-09-28
CN105664164B (zh) 2020-05-05
IL226490A (en) 2017-05-29
SG10201509631SA (en) 2015-12-30
CN103402521B (zh) 2016-01-20
EP2642999A1 (en) 2013-10-02
RS55545B1 (sr) 2017-05-31
US20120129853A1 (en) 2012-05-24
MX346201B (es) 2017-03-09
TW201630885A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
PH12016500939A1 (en) Methods of treatment using selective bcl-2 inhibitors
PH12018501827A1 (en) Cancer treatment
EA201290837A1 (ru) Лечение волчаночного нефрита с применением лаквинимода
JO3407B1 (ar) مركبات رباعي هيدرو بيرازولو بيريميدين
MD4635C1 (ro) Compuşi de chinolină substituiţi selectiv
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
HK1223093A1 (zh) 殺真菌組合物
EA025278B9 (ru) Антивирусная композиция против заключенных или незаключенных в оболочку днк- или рнк-вирусов
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
WO2012065102A3 (en) S-t-butyl protected cysteine di-peptide analogs and related compounds
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
BR112014011254A2 (pt) 2-tiopirimidinonas
MX337664B (es) Formulaciones para utilizarse en el control de incrustaciones de azufre en sistemas de agua industrial.
CA2895138C (en) Herbicidal agents containing aclonifen
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
WO2013013165A3 (en) Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
BR112013003740A2 (pt) composições algicidas sinergísticas incluindo derivados de hidrazona e cobre
AU2011262991A1 (en) Gemini virus replication inhibitor
WO2008008841A3 (en) Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders
EA201491876A1 (ru) Азотсодержащее бициклическое ароматическое гетероциклическое соединение
WO2011097027A3 (en) Methods for treating or inhibiting infection by clostridium difficile
UA42812U (ru) Использование мази тиотриазолина в качестве агента, обладающего фотопротекторными свойствами

Legal Events

Date Code Title Description
FG Grant or registration